Novo Nordisk A/S (NVO)
| Market Cap | 628.28B |
| Revenue (ttm) | 35.35B |
| Net Income (ttm) | 12.92B |
| Shares Out | 4.39B |
| EPS (ttm) | 2.87 |
| PE Ratio | 50.00 |
| Forward PE | 39.53 |
| Dividend | $0.67 (0.47%) |
| Ex-Dividend Date | Mar 22, 2024 |
| Volume | 5,900,099 |
| Open | 141.69 |
| Previous Close | 145.42 |
| Day's Range | 139.03 - 143.37 |
| 52-Week Range | 75.56 - 148.15 |
| Beta | 0.17 |
| Analysts | Strong Buy |
| Price Target | 140.50 (-1.73%) |
| Earnings Date | Aug 8, 2024 |
About NVO
Novo Nordisk A/S (Novo Nordisk) operates as a global healthcare company. The company manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. The company has a broad product portfolio across Diabetes and Obesity care and Rare disease, including a full portfolio of glucagon-like-peptide-1 (GLP-1) receptor agonists for the treatment of diabetes and obesity, modern insulins and human insulins. During 2023, there has been continued strong growth across therapy ... [Read more]
Financial Performance
In 2023, Novo Nordisk's revenue was 232.26 billion, an increase of 31.26% compared to the previous year's 176.95 billion. Earnings were 83.68 billion, an increase of 50.71%.
Financial numbers in DKK Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for NVO stock is "Strong Buy." The 12-month stock price forecast is $140.5, which is a decrease of -1.73% from the latest price.
News
Novo Nordisk and Eli Lilly Slide as Biden Blasts Weight-Loss Drug Prices
Novo Nordisk (NVO) American depositary receipts (ADRs) and Eli Lilly (LLY) shares lost ground Tuesday after U.S. President Joe Biden and Senator Bernie Sanders called out the companies in an op-ed for...
Weighing the Future of Weight Loss Drugs
How are obesity drugs impacting other industries? Julia Angeles discusses the future of weight loss drugs.
Joe Biden Suggests Novo Nordisk, Eli Lilly To Lower Prices For Its Popular Obesity Drugs
The President of the United States, Joe Biden, and Sen. Bernie Sanders, the Senate Chairman of the Health, Education, Labor, and Pensions Committee, have long been vocal about the exorbitant prices th...
Novo Nordisk must cut prices of weight-loss drug, Biden says in USA Today piece
U.S. President Joe Biden and Senator Bernie Sanders called on Novo Nordisk to cut prices of its Ozempic and Wegovy drugs for weight loss and diabetes, in an opinion piece by them published in USA Toda...
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 01 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
Eli Lilly and Novo Nordisk are ahead in manufacturing but need time to meet demand, says Louise Chen
Louise Chen, Cantor Fitzgerald analyst, joins CNBC's 'Squawk Box' to discuss Eli Lilly's surge over the past year, manufacturing, and more.
Healthcare: Best strategies to invest in pharma stocks
Novo Nordisk (NVO) and Eli Lilly (LLY) both made headlines recently with positive drug trial results for their respective GLP-1 weight-loss drugs, as well as their approval in China. While these names...
Novo Nordisk makes impairment loss of $816 mln in Q2
Novo Nordisk said on Wednesday it would recognise an impairment loss of about 5.7 billion Danish crowns ($816.72 million) in the second quarter of 2024, after its CLARION-CKD phase 3 trial failed to m...
Novo Nordisk stops the ocedurenone CLARION-CKD trial and recognises impairment loss
Bagsværd, Denmark, 26 June 2024 – Novo Nordisk today announced that the CLARION-CKD phase 3 trial failed to meet its primary endpoint and that it will recognise an impairment loss of around DKK 5.7 bi...
Ozempic craze: Novo Nordisk invests $4.1B in US to expand manufacturing
Novo Nordisk is ramping up the manufacturing capacity of its obesity-related drugs as demand for Wegovy and Ozempic continues to surge. It's pouring $4.1 billion to expand its facility.
Novo Nordisk Rises as Wegovy Is Approved in China
American depositary receipts (ADRs) of Danish drugmaker Novo Nordisk (NVO) rose Tuesday on the New York Stock Exchange (NYSE) after the company announced that its popular weight-loss drug Wegovy has b...
Novo Nordisk gains approval to sell weight-loss drug Wegovy in China
Novo Nordisk has gained approval to start marketing its blockbuster weight-loss drug Wegovy in China, opening the door for the Danish pharmaceutical giant to further boost sales of the medicine that h...
Novo Nordisk wins approval for its weight-loss drug from China
Novo Nordisk A/S (CPH: NOVO-B) climbed 3.0% to an all-time high on Tuesday after China approved the sale of its weight-loss treatment Wegovy. Year-to-date, shares of the pharmaceutical giant are now ...
Wegovy Approved In China—But Novo Nordisk Promises Existing Patients Priority Amid Shortages
Ozempic maker Novo Nordisk confirmed Tuesday its popular weight loss drug Wegovy had been approved for sale in China, a key victory for the Danish firm that opens the door to an enormous market, but t...
Novo Nordisk's Wegovy weight loss drug approved in China
Novo Nordisk said Tuesday that its Wegovy weight loss treatment has been approved in China for long-term weight management. The approval opens up the blockbuster drug for sale for those with obesity a...
Novo Nordisk says Semaglutide approved for long-term weight management in China
Novo Nordisk's drug Semaglutide has been approved in China for long-term weight management, the company said in a post on an official WeChat account on Tuesday.
Novo Nordisk Invests $4.1 Billion For New US Facility—Boosting Ozempic Production
Novo Nordisk will invest $4.1 billion to develop a new manufacturing facility in the U.S., which will be used to boost production for the company's weight loss and diabetes drugs Wegovy and Ozempic, t...
Wegovy-maker Novo Nordisk to spend $4.1 bln to boost US manufacturing
Obesity drug-maker Novo Nordisk will spend $4.1 billion to build a U.S. facility to fill injection pens for its hugely popular weight-loss treatment Wegovy and diabetes drug Ozempic, it said on Monday...
Novo Nordisk announces 4.1 billion USD investment to expand US manufacturing capacity adline
In 2024, Novo Nordisk plans to boost its current investments, aiming to allocate USD 6.8 billion towards production, a significant increase from the previous year's investment of USD 3.9 billion*.
Novo Nordisk to build $4.1 billion North Carolina facility to boost output of Wegovy, Ozempic
Novo Nordisk said it will spend $4.1 billion to boost the supply of its blockbuster weight loss drug Wegovy, diabetes treatment Ozempic and other injectable therapies. The investment will fund a new ...
Teva launches generic version of Novo Nordisk's diabetes drug Victoza
Teva Pharmaceuticals said on Monday it has launched the generic version of Danish drugmaker Novo Nordisk's drug Victoza to treat patients with type 2 diabetes.
China OKs Novo Nordisk's Type-2 diabetes treatment to enter its market
China's National Medical Products Administration has granted green lights for Novo Nordisk's insulin icodec injection used for the treatment of Type-2 diabetes among adults to enter the Chinese market...
Novo's Wegovy induces higher weight loss in women than men with same heart condition, study shows
Novo Nordisk's popular obesity drug Wegovy helped women with a common heart disease lose more weight than men who had the same condition, an analysis of study data published in a medical journal has s...
Novo Nordisk A/S: Mim8 demonstrated superior reductions in annualised bleeding rate (ABR) compared to on-demand and prior prophylaxis treatment in people with haemophilia A
FRONTIER2 data presented at ISTH 2024 showed that up to 95% of people, who had no prior prophylaxis treatment, experienced zero treated bleeds while on Mim8
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
Shares of Catalent Inc CTLT, which manufactures Elevidys, are trading higher with a strong session volume of 3.6 million compared to an average volume of 1.6 million.